Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q2 FY23 results · Jul–Sep 2022
Alkem Laboratories reported revenue from operations of ₹3,079.37 crore (up 10.0% from Q2 FY22) and net profit of ₹347.72 crore (down 37.7% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,079.37 | 2,799.99 | +10.0% | 2,576.38 | +19.5% |
| Other income | 50.67 | 41.96 | +20.8% | 51.41 | −1.4% |
| Total income | 3,130.04 | 2,841.95 | +10.1% | 2,627.79 | +19.1% |
| Profit before tax | 402.33 | 581.54 | −30.8% | 151.89 | +164.9% |
| Net profit for the period | 347.72 | 558.53 | −37.7% | 131.45 | +164.5% |
| Attributable to shareholders of the company | 330.84 | 544.26 | −39.2% | 127.64 | +159.2% |
| EPS, basic (₹) | 27.67 | 45.52 | −39.2% | 10.68 | +159.2% |
| Net margin (%) | 11.3 | 19.9 | 5.1 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,461.49 | 2,363.99 | +4.1% | 2,058.35 | +19.6% |
| Other income | 73.64 | 43.21 | +70.4% | 55.31 | +33.1% |
| Total income | 2,535.13 | 2,407.20 | +5.3% | 2,113.66 | +19.9% |
| Profit before tax | 401.56 | 568.73 | −29.4% | 159.79 | +151.3% |
| Net profit for the period | 350.69 | 558.01 | −37.2% | 140.10 | +150.3% |
| EPS, basic (₹) | 29.33 | 46.67 | −37.2% | 11.72 | +150.3% |
| Net margin (%) | 14.2 | 23.6 | 6.8 |
Consolidated
- Filed with BSE
- 12 Nov 2022, 12:46 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2022, 12:46 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE